Clinical advances and ongoing trials on mRNA vaccines for cancer treatment.
Lancet Oncol
; 23(10): e450-e458, 2022 10.
Article
in English
| MEDLINE | ID: covidwho-2042234
ABSTRACT
Years of research exploring mRNA vaccines for cancer treatment in preclinical and clinical trials have set the stage for the rapid development of mRNA vaccines during the COVID-19 pandemic. Therapeutic cancer vaccines based on mRNA are well tolerated, and the inherent advantage in ease of production, which rivals the best available conventional vaccine manufacture methods, renders mRNA vaccines a promising option for cancer immunotherapy. Technological advances have optimised mRNA-based vaccine stability, structure, and delivery methods, and multiple clinical trials investigating mRNA vaccine therapy are now enrolling patients with various cancer diagnoses. Although therapeutic mRNA-based cancer vaccines have not yet been approved for standard treatment, encouraging results from early clinical trials with mRNA vaccines as monotherapy and in combination with checkpoint inhibitors have been obtained. This Review summarises the latest clinical advances in mRNA-based vaccines for cancer treatment and reflects on future perspectives and challenges for this new and promising treatment approach.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Cancer Vaccines
/
Neoplasms
Type of study:
Prognostic study
Topics:
Vaccines
Limits:
Humans
Language:
English
Journal:
Lancet Oncol
Journal subject:
Neoplasms
Year:
2022
Document Type:
Article
Affiliation country:
S1470-2045(22)00372-2
Similar
MEDLINE
...
LILACS
LIS